If Regeneron decides to exercise its option, it will be liable to make milestone as well as royalty payments to ISA. Regeneron is developing cemiplimab with Sanofi (Read more: Regeneron in Strategic Immuno-Oncology Collaboration with ISA ). Clinical Hold Lifted on Alnylam/Sanofi's Fitusiran: The FDA has lifted the clinical hold that was placed on studies being conducted with Alnylam Pharmaceuticals ( ALNY - Free Report ) and Sanofi's fitusiran. The companies expect to resume dosing around year end in the studies including the phase II open-label extension ("OLE") study and the ATLAS phase III program. Dosing had been suspended following the observation of a fatal thrombotic serious adverse event ("SAE") in a patient with hemophilia A without inhibitors who was receiving fitusiran in the OLE study (Read more: Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran ).